to-the-point
New Retina Radio
Episode 38

Continuous Dosing in LADDER

The phase 2 LADDER study showed the Port Delivery System for ranibizumab was worthy of a phase 3 trial. Was the device able to deliver a continuous dose of therapy that was similar to what you'd find in monthly injection patients? Dilsher Dhoot, MD, reviews the pharmacokinetic data that researchers used to determine the rate of drug release and therapeutic benefit and previews the phase 3 ARCHWAY trial.

8/4/2020 | 7:39

More Episodes: